Of the various vaccine candidates being developed for the novel coronavirus, only a handful, if any, will ultimately be winners – along with the firms behind them. The majority of the candidates – and in some cases the firms behind them – will drift into obscurity. Despite this difficult landscape, however, there’s still money to be made by buy-and-hold investors in the biotech sector – even among small-cap plays. CLICK HERE.
Buy-And-Hold & Biotech
- by Sarah